The nitric oxide system in glucocorticoid-induced hypertension

被引:72
|
作者
Whitworth, JA
Schyvens, CG
Zhang, Y
Andrews, MC
Mangos, GJ
Kelly, JJ
机构
[1] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia
[2] Univ NSW, St George Hosp, Dept Med & Renal Med, Kogarah, NSW 2217, Australia
关键词
adrenocorticotrophic hormone; animal; cortisol; glucocorticoid-induced hypertension; human; hypertension; nitric oxide;
D O I
10.1097/00004872-200206000-00003
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The blood pressure-raising effects of adrenocortical steroids with predominantly glucocorticoid activity, both naturally occurring and synthetic, are well known. Recent evidence suggests that the nitric oxide system plays a key role in the hypertension produced by glucocorticoids. Glucocorticoid actions at various sites in the nitric oxide synthase (NOS) pathway may result in elevated blood pressure. These include: alterations in L-arginine availability or transport; NOS2 and NOS3 downregulation; reduced cofactor bioavailability; NOS uncoupling; a concomitant elevation in reactive oxygen species and removal of nitric oxide (NO) from the vascular environment; alterations in whole body antioxidant status; and erythropoietin induced resistance to NO. J Hypertens 20:1035-1043 (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:1035 / 1043
页数:9
相关论文
共 50 条
  • [31] Effects of Sepiapterin Supplementation and NOS Inhibition on Glucocorticoid-Induced Hypertension
    Thida, Mya
    Earl, John
    Zhao, Yan
    Wang, Hans
    Tse, Chi S.
    Vickers, Janine J.
    Sutton, Matthew
    Ong, Sharon L. H.
    Mori, Trevor A.
    Croft, Kevin D.
    Whitworth, Judith A.
    Zhang, Yi
    AMERICAN JOURNAL OF HYPERTENSION, 2010, 23 (05) : 569 - 574
  • [32] Glucocorticoid-induced osteoclastogenesis is compromised in glucocorticoid-induced AVN in SLE patients
    Oh, Brian
    Kaneko, Kaichi
    Chen, Hao
    Krez, Alexandra
    Heilbronner, Alison
    Zeng, Steven
    Park, Peter Sang
    Lee, Ye-Ji
    Fujii, Takayuki
    Kim, Haemin
    Mun, Sehwan
    Bae, Seyeon
    Pannellini, Tania
    Lane, Joseph
    Hansen, Derek
    Mintz, Douglas
    Bockman, Richard
    Stein, Emily
    Park-Min, Kyung-Hyun
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 250 - 250
  • [33] The serum- and glucocorticoid-induced kinase in DOCA–salt hypertension
    Friedrich C. Luft
    Journal of Molecular Medicine, 2006, 84 : 709 - 711
  • [34] Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize
    Yorio, Thomas
    Patel, Gaurang C.
    Clark, Abbot F.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2020, 15 (03) : 145 - 157
  • [35] ENHANCED RENIN SECRETION IN ADRENALECTOMIZED RATS WITH GLUCOCORTICOID-INDUCED HYPERTENSION
    KASSER, A
    WAEBER, B
    NUSSBERGER, J
    BURRIS, J
    BRUNNER, HR
    CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1985, 7 (11) : 1619 - 1628
  • [36] Mouse strain differences in development of glucocorticoid-induced ocular hypertension
    Patel, Pinkal D.
    Patel, Gaurang
    Geisert, Eldon E.
    Millar, J. Cameron
    Clark, Abbot F.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [37] Microvascular endothelial cell death in glucocorticoid-induced hypertension.
    Vogt, CJ
    Zweifach, BW
    SchmidSchonbein, GW
    FASEB JOURNAL, 1997, 11 (03): : 2706 - 2706
  • [38] Glucocorticoid-induced osteoporosis
    Fine, JB
    Fine, RM
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1998, 37 (05) : 346 - 347
  • [39] Glucocorticoid-induced osteonecrosis
    Robert S. Weinstein
    Endocrine, 2012, 41 : 183 - 190
  • [40] Glucocorticoid-induced myopathy
    Rodrigues Pereira, Rosa Maria
    de Carvalho, Jozelio Freire
    JOINT BONE SPINE, 2011, 78 (01) : 41 - 44